212 related articles for article (PubMed ID: 18570771)
1. [Complete remission after Rituximab treatment in refractory hairy cell leukemia].
Petruskevicius I; Bukh A; Mertz H; Johnsen HE
Ugeskr Laeger; 2008 Jun; 170(26-32):2350. PubMed ID: 18570771
[TBL] [Abstract][Full Text] [Related]
2. Rituximab as treatment for minimal residual disease in hairy cell leukaemia.
Cervetti G; Galimberti S; Andreazzoli F; Fazzi R; Cecconi N; Caracciolo F; Petrini M
Eur J Haematol; 2004 Dec; 73(6):412-7. PubMed ID: 15522063
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia.
Lauria F; Lenoci M; Annino L; Raspadori D; Marotta G; Bocchia M; Forconi F; Gentili S; La Manda M; Marconcini S; Tozzi M; Baldini L; Zinzani PL; Foà R
Haematologica; 2001 Oct; 86(10):1046-50. PubMed ID: 11602410
[TBL] [Abstract][Full Text] [Related]
4. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
5. [Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine].
Zák P; Chrobák L; Dĕdic K; Podzimek K
Vnitr Lek; 2000 Oct; 46(10):697-703. PubMed ID: 11344629
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
[TBL] [Abstract][Full Text] [Related]
7. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.
Else M; Osuji N; Forconi F; Dearden C; Del Giudice I; Matutes E; Wotherspoon A; Lauria F; Catovsky D
Cancer; 2007 Nov; 110(10):2240-7. PubMed ID: 17886250
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab.
Hensel M; Ho AD
Am J Hematol; 2003 May; 73(1):37-40. PubMed ID: 12701118
[TBL] [Abstract][Full Text] [Related]
9. Cladribine in hairy cell leukemia.
Belani R; Saven A
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
[TBL] [Abstract][Full Text] [Related]
10. Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab.
Quach H; Januszewicz H; Westerman D
Haematologica; 2005 Nov; 90 Suppl():ECR26. PubMed ID: 16266917
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
[TBL] [Abstract][Full Text] [Related]
12. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
[TBL] [Abstract][Full Text] [Related]
14. Which role for rituximab in hairy cell leukemia? Reflections on six cases.
Malfuson JV; Fagot T; Konopacki J; Souleau B; Cremades S; de Revel T
Acta Haematol; 2010; 123(2):110-6. PubMed ID: 20051682
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular complete remission in a case of variant hairy cell leukemia treated with DHAP followed by high-dose chemotherapy plus rituximab.
Goldaniga M; Guffanti A; Gianelli U; Magni M; Lambertenghi Deliliers G; Baldini L
Haematologica; 2004 Nov; 89(11):ECR41. PubMed ID: 15533846
[No Abstract] [Full Text] [Related]
16. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.
Del Poeta G; Del Principe MI; Buccisano F; Maurillo L; Capelli G; Luciano F; Perrotti AP; Degan M; Venditti A; de Fabritiis P; Gattei V; Amadori S
Cancer; 2008 Jan; 112(1):119-28. PubMed ID: 17999417
[TBL] [Abstract][Full Text] [Related]
17. Rituximab: a useful drug for a repeatedly relapsed hairy cell leukemia patient.
Pollio F; Pocali B; Palmieri S; Morabito P; Scalia G; Del Vecchio L; Ferrara F
Ann Hematol; 2002 Dec; 81(12):736-8. PubMed ID: 12483372
[TBL] [Abstract][Full Text] [Related]
18. [Hairy cell leukemia. An alternative method for the detection of minimal residual disease using flow cytometry].
Bengio R; Narbaitz M; Palacios F; Scolnik M; Sarmiento M
Medicina (B Aires); 2000; 60 Suppl 2():71-6. PubMed ID: 11188936
[TBL] [Abstract][Full Text] [Related]
19. [Successful rituximab treatment in a patient with refractory hairy cell leukemia-Japanese variant and suffering from acute respiratory distress].
Makita M; Nakamura K; Kono A
Rinsho Ketsueki; 2005 Nov; 46(11):1196-201. PubMed ID: 16440803
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of hairy cell leukemia variant with rituximab.
Narat S; Gandla J; Dogan A; Mehta A
Leuk Lymphoma; 2005 Aug; 46(8):1229-32. PubMed ID: 16085567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
